XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events	9 Months Ended
Sep. 30, 2021
Subsequent Events
Subsequent Events	14. Subsequent Events Affitech Agreement On October 6, 2021, the Company entered into a commercial payment purchase agreement (the “Affitech Agreement”) with Affitech Research AS (“Affitech”), a Norwegian biotech company. Pursuant to the Affitech Agreement, the Company purchased a future stream of commercial payment rights to F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.’s faricimab from Affitech for $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million to Affitech based upon the achievement of certain regulatory and sales milestones. Novartis International NIS793 Milestone On November 3, 2021, the Company was notified it had earned a $35.0 million milestone payment pursuant to the Anti-TGFβ Antibody License Agreement. The milestone was triggered upon dosing of the first patient in Novartis’ NIS793 Phase 3 clinical trial in October 2021.

Subsequent Events

9 Months Ended

Sep. 30, 2021

Subsequent Events

Subsequent Events

14. Subsequent Events

Affitech Agreement

On October 6, 2021, the Company entered into a commercial payment purchase agreement (the “Affitech Agreement”) with Affitech Research AS (“Affitech”), a Norwegian biotech company. Pursuant to the Affitech Agreement, the Company purchased a future stream of commercial payment rights to F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.’s faricimab from Affitech for $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million to Affitech based upon the achievement of certain regulatory and sales milestones.

Novartis International NIS793 Milestone

On November 3, 2021, the Company was notified it had earned a $35.0 million milestone payment pursuant to the Anti-TGFβ Antibody License Agreement. The milestone was triggered upon dosing of the first patient in Novartis’ NIS793 Phase 3 clinical trial in October 2021.